Polyneuron Pharmaceuticals AG
Polyneuron Pharmaceuticals AG is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Polyneuron Pharmaceuticals AG.
Polyneuron Pharmaceuticals AG is a company.
Key people at Polyneuron Pharmaceuticals AG.
Key people at Polyneuron Pharmaceuticals AG.
Polyneuron Pharmaceuticals AG is a Swiss biotechnology company developing precision therapies for antibody-mediated autoimmune diseases, particularly those affecting the nervous system.[1][2][3] Its core Antibody-Catch™ platform uses injectable glycopolymers to selectively eliminate pathological autoantibodies while preserving the rest of the immune system, targeting rare conditions like anti-MAG neuropathy and multifocal motor neuropathy with high unmet needs.[1][3][4] The company serves patients with devastating autoimmune disorders of the peripheral nervous system, addressing the lack of effective, safe treatments by offering a novel immunomodulatory approach that could enable breakthrough therapies.[1][2][4]
Founded in 2014 as a spin-off from the University of Basel's Department of Pharmaceutical Sciences, Polyneuron advanced lead candidate PN-1007 through preclinical milestones, including orphan drug designation from the EMA and promising in vivo data published in PNAS, before it reached discontinued status.[1][4][6] Growth included grants from CTI (Innosuisse), BaseLaunch, and EMA scientific advice, with a team expanding to include experts in neuroimmunology and carbohydrate chemistry.[4]
Polyneuron emerged in 2014 from the University of Basel's Department of Pharmaceutical Sciences, where founders identified a gap in treating antibody-mediated autoimmune diseases driven by anti-carbohydrate autoantibodies.[1][3] Co-founders Ruben Herrendorff (CEO) and Pascal Zenobi-Wong (CSO) leveraged their expertise in pharmaceutical sciences—Ruben in chemical synthesis, assay development, and in vivo pharmacology for lead PN-1007, and Pascal in preclinical development and regulatory interactions—both holding advanced degrees from Swiss universities.[1]
Early traction built through a CTI-funded collaboration with the University of Basel (CHF 418,900), patent filing for Antibody-Catch™, and promising animal model data for anti-MAG neuropathy.[4] Pivotal moments included Venture Kick support, BaseLaunch grants (CHF 130,000 total), hiring of Michael Wacker (former GlycoVaxyn CSO) as Chief Business Officer, EMA orphan drug designation for PN-1007, PNAS publication, and initiation of clinical trial-enabling studies by around 2018.[1][4]
Polyneuron rides the wave of precision immunology, where targeted autoantibody depletion addresses failures of broad immunosuppressants in rare neurological autoimmunities—a market underserved amid rising autoimmune disease prevalence.[1][2][3] Timing aligns with advances in glycopolymer design and regulatory support for orphan drugs, amplified by Switzerland's biotech hub status (Basel ecosystem with EMA proximity).[3][4]
Favorable forces include CTI/Innosuisse funding for de-risking, EMA endorsements accelerating paths to clinic, and investor interest in platform technologies amid $212M precedents like GlycoVaxyn's GSK exit.[1][4] Polyneuron influences the ecosystem by validating Antibody-Catch™ for nervous system applications, inspiring spin-offs and contributing talent—e.g., Herrendorff's move to NXI Therapeutics CEO in 2022—while highlighting unmet needs in anti-carbohydrate autoantibody therapies.[2][4]
Post-PN-1007 discontinuation, Polyneuron's platform endures with PN-1018 in preclinical for motor neuron disease and pending candidates like PN-032/PN-056 for transplantation, signaling pivot potential toward expanded autoimmune and transplant indications.[6] Next steps likely involve partnerships or funding to revive clinical pipelines, leveraging EMA history and Basel network amid biotech M&A trends.
Shaping trends—AI-driven epitope mapping, glycobiology advances, and orphan drug incentives—could propel selective therapies, evolving Polyneuron from neuropathy pioneer to broader immunology player. Its spin-off roots underscore biotech resilience, positioning it to deliver on Antibody-Catch™'s promise for patients long underserved by imprecise treatments.[1][6]
